Ultragenyx Pharmaceutical (RARE) Minority Interest (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 4 years of Minority Interest data on file, last reported at $7.0 million in Q1 2026.

• Quarterly Minority Interest changed 0.0% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $7.0 million, changed 0.0% from the prior year.
• Minority Interest held at $7.0 million in Q1 2026 per RARE's latest filing, from $7.0 million in the prior quarter.
• Across five years, Minority Interest topped out at $7.0 million in Q3 2024 and bottomed at $7.0 million in Q3 2024.
• The 3-year median for Minority Interest is $7.0 million (2024), against an average of $7.0 million.
• Peak annual rise in Minority Interest reached 0.0% in 2025, while the deepest fall reached 0.0% in 2025.
• Tracing RARE's Minority Interest over 3 years: stood at $7.0 million in 2024, then changed by 0.0% to $7.0 million in 2025, then changed by 0.0% to $7.0 million in 2026.
• Per Business Quant, the three latest RARE Minority Interest figures stand at $7.0 million (Q1 2026), $7.0 million (Q4 2025), and $7.0 million (Q3 2025).

Peer Comparison